Aimovig vs Ajovy
A side-by-side look at two neurology medications advertised on TV. Informational only — not medical advice.
| US Aimovig | US Ajovy | |
|---|---|---|
| Generic name | erenumab | fremanezumab |
| Drug class | CGRP Receptor Antagonist (Biologic) | CGRP Antagonist (Biologic) |
| Treats | Migraine prevention | Migraine prevention |
| Category | Neurology | Neurology |
| Manufacturer | Amgen/Novartis | Teva |
| Year approved | 2018 | 2018 |
| FDA warning | No boxed warning | No boxed warning |
| Est. TV ad spend | $100M | $70M |
| Common side effects | Constipation, Injection site reactions, Muscle cramps, High blood pressure | Injection site reactions, Allergic reactions |
Frequently asked questions
Is Aimovig or Ajovy better?
Neither is universally "better." Aimovig (erenumab) and Ajovy (fremanezumab) are both used for neurology, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Aimovig and Ajovy?
Aimovig is a CGRP Receptor Antagonist (Biologic) made by Amgen/Novartis, while Ajovy is a CGRP Antagonist (Biologic) made by Teva. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Aimovig has the larger estimated TV advertising budget of the two.